drugset / Trial / NCT04082520

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

NCT04082520

Phase 2 Recruiting 42 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill tumor cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment. WHO Grade I and Cohort WHO II/III cohorts will be evaluated.

Timeline

Start
2020-04-14
Primary completion
2027-09-04
Completion
2032-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DOTATATE Peptide Intravenous